Tag results:
clinical trial
Mesenchymal Cell News
miR-204–Containing Exosomes Ameliorate GVHD-Associated Dry Eye Disease
[Science Advances] Investigators reported that exosomes from MSCs administered as eye drops notably alleviated graft-versus-host disease-associated dry eye disease by suppressing inflammation and improving epithelial recovery in mice and humans.
Mesenchymal Cell News
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase II Clinical Trial of COVI-MSC in COVID-19 Patients with Persistent Pulmonary Compromise after Recovery (Long-Hauler)
[Sorrento Therapeutics, Inc.] Sorrento Therapeutics, Inc. announced receipt of clearance from ANVISA to proceed with a Phase IIa randomized, placebo-controlled study of intravenous allogeneic adipose-derived MSC to treat post COVID-19 “long haul” pulmonary compromise.
Hematopoiesis News
IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients...
[IMV Inc.] IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.
Muscle Cell News
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-Specified Matched External Control in Part II of Study SRP-9001-102 for the...
[Sarepta Therapeutics] Sarepta Therapeutics, Inc. announced topline results from Part II of Study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 in 41 patients with Duchenne muscular dystrophy.
Human Immunology News
Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
[Rubius Therapeutics, Inc.] Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.
Neural Cell News
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase I Clinical Trial of UB-312
[Vaxxinity, Inc.] Vaxxinity, Inc. announced that the first patient with Parkinson’s disease has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase I clinical trial, following completion of Part A of the Phase I trial in healthy volunteers.